

Press release February 20th, 2019, at 13.00 CET.

Sedana Medical establishes sedation research foundation

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the establishment of the Sedana Medical Research Foundation, creating a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill patients.

One of Sedana Medical's missions is to improve patient outcomes through medical innovation. Sedana Medical Research Foundation is established to stimulate and support international research in the field of sedation of mechanically ventilated Intensive Care Unit (ICU) patients.

"By supporting sedation research of critically ill ICU patients, our hope is that Sedana Medical Research Foundation will be a vital contributor in expanding knowledge in this important field", said Peter Sackey, Chief Medical Officer at Sedana Medical.

Sedana Medical will grant 1-3 individual academic researchers between €10 000 and €30 000 per year, for up to two years, through Sedana Medical Research Foundation. The grant for 2019/2020 will prioritize research targeting pulmonary and cognitive outcomes in mechanically ventilated patients.

Every year about 15 million patients are hospitalized and cared in ICU's globally. Of these patients, a large proportion need respiratory support and mechanical ventilation. To facilitate the comfort and safety of these patients, sedation is often used. The optimal sedative drug and strategy is yet to be determined.

For additional information, please contact:

Peter Sackey, CMO, Sedana Medical AB

Mobile: +46 70 771 03 64

e-post: peter.sackey@sedanamedical.com

Sedana Medical is listed on Nasdaq First North in Stockholm.

Erik Penser Bank (+46 8 463 83 00, certifiedadviser@penser.se) is Certified Adviser to Sedana Medical.

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane).

Sedana Medical has direct sales in the Nordic countries, Germany, France, Great Britain and Spain as well as external distributors in the rest of Europe, Canada, Australia, Japan and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.